Confident Investing Starts With TipRanks Premium

Get 55% Off
TipRanks
Go Ultimate55% OFF

Tristel (TSNLF) Stock Price & Analysis

TSNLF Stock Chart & Stats

$5.42$0.01(0.18%)
At close: 4:00 PM EDT
$5.25$5.5$5.75$65 May9 Jul24 Jul4 Aug
Day’s Range
$4.92 - $5.92
52-Week Range
$3.24 - $6.37
Previous Close
$5.41
Volume
N/A
Average Volume (3M)
0
Market Cap
$260.66M
Enterprise Value
$181.84M
Total Cash (Recent Filing)
$16.00M
Total Debt (Recent Filing)
$5.86M
Price to Earnings (P/E)
24.3
Beta
0.27
Next Earnings
Feb 22, 2027 (Est.)
EPS Estimate
N/A
Next Dividend Ex-Date
Nov 26, 2026
Dividend Yield
3.48%

Bulls Say, Bears Say

Bulls Say

Proprietary Technology And Defensible Market Position

A proprietary technology position supported by patents, applications and difficult-to-replicate know-how can protect product differentiation over several years. This strengthens Tristel’s ability to win regulated healthcare accounts, support premium margins and build adoption as clinical evidence and guidelines expand.

Sustained Growth With Expanding Margins

Record revenue, double-digit growth and a 31% adjusted EBITDA margin indicate that demand is scaling without eroding profitability. The combination supports reinvestment in commercial expansion, clinical evidence and product development while reinforcing management’s long-term growth model.

Strong Cash Generation And Debt-free Balance Sheet

Strong operating cash flow and a debt-free position give Tristel financial flexibility to fund sales expansion, research, launches and potential partnerships internally. The cash balance also reduces balance-sheet pressure, allowing management to pursue growth while continuing progressive dividends.

Bears Say

Legacy Product Declines And Regional Competition

Declining legacy products and competitive or tender-related pressure can offset growth from newer offerings, particularly in mature markets. If these headwinds persist, they could make consolidated growth less predictable and require greater commercial investment to defend existing positions.

Higher Impairments And Cost Burden

Higher depreciation, amortization and impairment charges reduce reported earnings and may signal that some investments are producing less value than originally expected. Even if the impairment is one-off, it highlights the need for disciplined product investment and effective capital allocation.

Execution Risk In New Product Expansion

Unifoam offers a new route to growth, but its commercial contribution depends on successful trials, registration and regulatory approval. Delays or weaker adoption could postpone returns on development and launch spending, while adding execution complexity as Tristel expands beyond established products.

Tristel News

TSNLF FAQ

What was Tristel’s price range in the past 12 months?
Tristel lowest stock price was $3.24 and its highest was $6.37 in the past 12 months.
What is Tristel’s market cap?
Tristel’s market cap is $260.66M.
When is Tristel’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Tristel’s earnings last quarter?
Tristel released its earnings results on Oct 19, 2026. The company reported $0.112 earnings per share for the quarter, missing the consensus estimate of $0.114 by -$0.001.
Is Tristel overvalued?
According to Wall Street analysts Tristel’s price is currently Undervalued.
Does Tristel pay dividends?
Tristel pays a Semiannually dividend of $0.124 which represents an annual dividend yield of 3.48%. See more information on Tristel dividends here
What is Tristel’s EPS estimate?
Tristel’s EPS estimate for its next earnings report is not yet available.
What happened to Tristel’s price movement after its last earnings report?
Tristel reported an EPS of $0.112 in its last earnings report, missing expectations of $0.114. Following the earnings report the stock price went down -5.41%.
Which hedge fund is a major shareholder of Tristel?
Currently, no hedge funds are holding shares in TSNLF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology